Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd. operates as a clinical stage biotechnology company. It engages in the research and development of biotechnological and pharmaceutical products. The firm specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple Sclerosis, Crohn's disease and KRAS+ NSCLC. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. It specializes in developing transformative therapies for neurodegenerative and lung diseases. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

LONDON, Sept. 27, 2021 (GLOBE NEWSWIRE) -- On 20 August 2021, Tiziana Life Sciences Plc (“Old Tiziana”) announced that it has formally commenced its strategic plan to change its corporate structure by establishing Tiziana Life Sciences Ltd (“New Tiziana”), a Bermuda-incorporated company, as the ultimate parent company of the of the Tiziana Group, to be effected by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the “Scheme”).

Tiziana Life Sciences Plc - Results of Court Meeting and General Meeting

Interim results from Tiziana Life Sciences PLC (NASDAQ:TLSA, LSE:TILS, FRA:RTRA, OTC:TIZAF) revealed the significant progress made by the drug developer in the first half of the year. In the six-month period to 30 June, the group was able to provide the first early demonstration that its monoclonal antibody (mAB) treatment, Foralumab, could be administered nasally using the local and lymphatic immune systems directly.

Tiziana Life Sciences' half-term report reveals it has made progress on all fronts

Interim results from Tiziana Life Sciences PLC revealed the significant progress made by the drug developer in the first six months of the year. In six month period to June 30, the group was able to provide the first early demonstration that its monoclonal antibody (mAB) treatment, Foralumab, could be administered nasally using the local and lymphatic immune systems directly.

Tiziana Life Sciences half-term report reveals it has made progress on all fronts

Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need

Tiziana Life Sciences plc - Interim Results for the Six Months Ended 30 June 2021

How it is doing Shares have soared recently on the potential for Tiziana's (LON:TILS) TZLS-501 to be useful for people severely ill with coronavirus-related complications. TZLS-501 is a class of monoclonal antibody (mAb) called an anti-interleukin-6 receptor, or anti-IL6R for short.

Tiziana Life Sciences upbeat on potential for coronavirus treatment

NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, will host a conference call and audio webcast on Wednesday, September 8, at 4:15 p.m. ET to discuss its recently announced exclusive license agreement to evaluate Foralumab, the Company's novel, fully human anti-CD3 monoclonal antibody, in conjunction with allogenic CAR T candidates for cancer treatment.

Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Tiziana Life Sciences plc Posting of Scheme Document and Notice of Meetings

Precision Biosciences

Shares in Tiziana Life Sciences PLC raced 20% higher in the opening minutes of trading on Wall Street after the group inked an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL). The tie-up takes it into the exciting arena of CAR-T therapy with the pair looking to use Tiziana's foralumab monoclonal antibody (mAb) to enhance the next generation of cancer treatments.

Tiziana Life Sciences races at US open after exclusive licensing agreement with Precision BioSciences

Precision BioSciences Inc (NASDAQ: DTIL) and Tiziana Life Sciences plc (NASDAQ: TLSA) have announced an exclusive license agreement for Tiziana's foralumab. The companies plan to explore the fully human anti-CD3 monoclonal antibody as an agent to induce tolerance of allogeneic CAR T cells.

Precision BioSciences, Tiziana Life Ink Foralumab Deal For Cancer Indications

Tiziana Life Sciences PLC surged 19% to 73p after signing an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL). The pair will explore the use of Tiziana's foralumab monoclonal antibody (mAb) to enhance the next generation of CAR-T therapies.

Tiziana Life Sciences surges on exclusive licensing agreement with Precision BioSciences

Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) said it has inked an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL) to explore the use of Tiziana's foralumab monoclonal antibody (mAb) to enhance the next generation of CAR-T therapies. CAR-T, or chimeric antigen receptors cell therapy, is at the vanguard of treating blood-borne cancers, and major acquisitions by Celgene (now owned by Bristol Myers Squibb) and Gilead Sciences (NASDAQ:GILD) underscore the interest in this emerging area of biotechnology.

Tiziana Life Sciences inks exclusive licensing deal with US group Precision BioSciences that takes it into CAR-T therapy

DURHAM, N.C., NEW YORK & LONDON--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, and Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS), a clinical stage biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced an exclusive license agreement to explore Tiziana's foralu

Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment

Tiziana Life Sciences Plc told investors it has formally begun its strategic plan to change its corporate structure. It has established a Bermuda-incorporated company Tiziana Life Sciences Ltd which is the ultimate parent company of the Tiziana Group.

Tiziana Life Sciences set for Nasdaq move

LONDON and NEW YORK, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Old Tiziana") a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases today announces that it has formally commenced its strategic plan to change its corporate structure by establishing Tiziana Life Sciences Ltd (“New Tiziana”), a Bermuda-incorporated company, as the ultimate parent company of the of the Tiziana Group. The reorganisation will be achieved by a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme").

Tiziana Life Sciences plc files scheme of arrangement to effect a corporate reorganisation and, if approved, the delisting of its ordinary shares in London and the direct listing of common shares in the new parent company of the Tiziana group on NASDAQ

Los Angeles, California--(Newsfile Corp. - August 18, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tesla, Inc. ("Tesla" or "the Company") (NASDAQ: TLSA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. The NHTSA opened an investigation into Tesla's Autopilot system as reported by...

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Tesla, Inc. and Encourages Investors with Losses to Contact the Firm

A peer-reviewed scientific article has underscored the potential of Tiziana Life Sciences PLC's (NASDAQ:TLSA, LON:TILS) monoclonal antibody nasal spray in people with mild-to-moderate Covid. The report in the Frontiers in Immunology showed Foralumab produced a significant reduction in lung inflammation as assessed by a CT scan.

Tiziana Life Sciences: Peer reviewed scientific article underscores the potential of monoclonal antibody nasal spray as a take-home Covid treatment

NEW YORK and LONDON, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces publication of a scientific article in the peer-reviewed journal Frontiers in Immunology titled " Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inﬂammation and Blood Inﬂammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study "(1). The study was completed in collaboration with scientific teams at the Harvard Medical School (Boston, USA) and INTRIALS, a full-service Latin American CRO based in São Paulo, Brazil. The aim of the study was to assess safety of intranasal Foralumab and evaluate its potential benefits in treating immune hyperactivity and lung inflammation in mild to moderate COVID-19 patients who were outpatients at the Santa Casa de Misericordia de Santos Hospital in Brazil. Thirty-nine patients were randomized into three cohorts: no Foralumab treatment (control), nasal Foralumab (100 ug) + Dexamethasone (6 mg orally on days 1-3), and nasal Foralumab (100 ug) alone administered for 10 consecutive days. All arms were allowed to continue standard of care medications. To view the online publication, please click here: http://journal.frontiersin.org/article/10.3389/fimmu.2021.709861/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Immunology&id=709861

Tiziana Announces Publication of a Peer Reviewed Article on Data from the Clinical Trial with Intranasally Administered Foralumab, Its Proprietary Fully Human Anti-CD3 Monoclonal Antibody, in Mild to Moderate COVID-19 Patients in Brazil

London, United Kingdom--(Newsfile Corp. - August 16, 2021) - Tiziana Life Sciences plc (NASDAQ:TLSA) today announced that Dr. Kunwar Shailubhai, CEO & CSO will be attending the Q3 Virtual Investor Summit.  Event Q3 Investor Summit Date August 17-18th, 2021 Presentation

Tiziana Life Sciences plc Invites You to Join Us at the Q3 Virtual Investor Summit

Tiziana Life Sciences (NASDAQ: TLSA) shares are trading higher by 16% at $2.10 as traders circulate a June 17 press release from the company titled 'Tiziana Responds to UK Call for Development of Innovative 'Take Home' Treatments for COVID-19 Disease.' Tiziana Life Sciences is a clinical-stage biotechnology company that specializes in developing transformative therapies for autoimmune and inflammatory diseases, degenerative diseases and cancer-related to the liver.

Why Tiziana Life Sciences Shares Are Trading Higher Today

THIS ANNOUNCEMENT IS FOR US ADS HOLDERS ONLY

Tiziana Life Sciences plc - ADS Ex-Dividend Date Scheduled for July 09, 2021

LONDON and NEW YORK, July 02, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that the Forms 20-F and F-6 filed by Accustem Sciences Limited with the SEC have been declared effective, enabling the completion of the in specie distribution and spin out of Accustem Sciences Limited. These documents together can be found at www.accustem.com

Tiziana Life Sciences plc - Distribution Dates for shares and ADRs in Accustem Sciences Limited

NEW YORK and LONDON, June 30, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces an interview with the Chairman of its' Scientific Advisory Board and Professor of Neurology at Harvard Medical School, Dr Howard Weiner is to air on Bloomberg Markets with Matt Miller and Amanda Lang today at 1.50pm ET/6.50pm BST.

Dr Howard Weiner, Chairman of the Tiziana Scientific Advisory Board, to give an interview on Bloomberg Markets at 1.50pm ET today

LONDON, June 25, 2021 (GLOBE NEWSWIRE) -- At the Annual General Meeting of the Company held at 10.00 a.m. on 25 June 2021, all of the resolutions were duly passed.

Tiziana Life Sciences plc (the "Company") Result of Annual General Meeting

The stock price of Tiziana Life Sciences plc (NASDAQ: TLSA) increased by over 6% pre-market. This is why it happened.

TLSA Stock Price Increases Over 6% Pre-Market: Why It Happened

Tiziana Life Sciences PLC (NASDAQTLSA, LON:TILS) said it has signed a deal with contract research group FHI Clinical to carry out a phase II, proof-of-concept study on its nasally-administered antibody treatment for Covid. Foralumab will be given to hospitalised patients with severe coronavirus as part of the Brazil trial that will build on earlier work in mild-to-moderate cases which confirmed the safety and tolerability of the drug as well as its potential efficacy.

News for Tiziana Life Sciences Ltd Stock (TLSA)